Vector Models and Indexing for CDMO Pharmacovigilance

Data Characteristics

Data in CDMO (Contract Development and Manufacturing Organization) pharmacovigilance primarily originates from clinical trial reports, real-world study data, post-market adverse event reports (ADRs), drug labeling, and regulatory documents. This data is typically unstructured text, including PDFs, Word documents, structured database exports (e.g., CSV or XML for adverse event reports), and scanned documents. Update frequency is high, especially after new drug launches and during clinical trials. Document structures are complex, containing medical terminology, drug names, dosages, patient characteristics, adverse event descriptions, and event times. Adverse event descriptions are often free-text and lack standardized formats. Fields include dosage units (mg, g, ml), frequency units (times/day, week), and event severity (mild, moderate, severe).

Constraints Imposed by These Characteristics on Vector Models and Indexing

The complexity and high update frequency of CDMO pharmacovigilance data impose specific requirements on vector models and indexing. Free-text adverse event descriptions require robust semantic understanding; general vector models may struggle to capture subtle nuances in specialized medical terminology. Multi-source heterogeneous data necessitates flexible data ingestion and preprocessing mechanisms for the indexing system. High update frequency means the index must support efficient incremental updates to avoid resource consumption and latency from full rebuilds. The prevalence of medical jargon and abbreviations can lead to inaccurate tokenization, affecting the quality of vector representations. Furthermore, the ability to process time-series data is crucial, for instance, the progression of adverse events, requiring the index to support time-dimensional retrieval and analysis.

Configuration Settings

Configuration Item	Suggested Value	Rationale
`Chunk size` (Chunk Length)	`500–800 characters`	Accommodates long sentences and paragraphs in medical texts, ensuring semantic completeness.
`Chunk overlap` (Chunk Overlap)	`50–100 characters`	Ensures contextual continuity and prevents critical information from being split.
`Recall count` (Recall Count)	`Top 10–20 items`	Improves recall rate, covering more potentially relevant adverse event reports.
`Similarity threshold` (Similarity Threshold)	Calibrate based on actual measurements	Balances recall and precision, reducing interference from irrelevant information.
`Rerank result count` (Rerank Return Count)	`5 items`	Prioritizes the most relevant results, improving analysis efficiency for engineers.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds`	Handles parsing time for large clinical trial reports and complex PDF documents.

Three Common Pitfalls

Knowledge base indexes remain in an "unfinished" state for extended periods. Common causes include file parsing timeouts or slow vector embedding service responses.
Retrieval results contain numerous irrelevant or low-relevance documents. This typically occurs because the vector model fails to effectively understand specialized medical terminology, or an improper chunking strategy leads to semantic fragmentation.
New data is not immediately retrievable after file upload. This can be due to the index not being configured for real-time or near real-time updates, or the incremental update mechanism not triggering correctly.

How to Verify Correct Configuration

Upload various types of pharmacovigilance documents (PDF, DOCX, TXT) and check if their index status displays "Completed".
Perform searches using queries containing specialized medical terminology. Verify that the recalled results include highly relevant adverse event reports.
Simulate the inflow of new adverse event report data. Check if the indexing system completes incremental updates within the specified time and if the new data is retrievable.
Through the FastGPT interface, confirm that the Embedding model and Rerank model are as expected, and check their invocation logs for any anomalies.

Note: The values provided are common starting points. It is recommended to measure and adjust these configurations based on your own data samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.